Last updated: February 23, 2026
What Is NDC 42291-0927?
NDC 42291-0927 corresponds to Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA for the acute and preventative treatment of migraine. It is marketed under the brand name Nurtec ODT. Rimegepant initially launched in 2020 and competes primarily with other CGRP inhibitors and triptans within the migraine treatment market.
Market Size and Growth Dynamics
The migraine therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 6.4% from 2022 to 2028, reaching $5.8 billion globally.[1] Rimegepant's market share increased with its dual-indication approval, making it a significant player. In 2022, the treatment was estimated to generate global sales of approximately $450 million.[2]
Key Market Drivers
- Growing migraine prevalence: Approximately 1 billion people worldwide suffer from migraine.[3]
- Shift towards CGRP therapies: Patients and physicians favor CGRP antagonists for their efficacy and safety over older therapies.
- Patient preference for oral formulations: Nurtec ODT’s oral disintegrating tablet appeals to a broad patient base, including those with nausea or difficulty swallowing.
Competition Landscape
- Erenumab (Aimovig): An injectable CGRP monoclonal antibody.
- Fremanezumab (Ajovy): An injectable anti-CGRP.
- Galcanezumab (Emgality): An injectable CGRP monoclonal antibody.
- Sumatriptan (Imitrex): A triptan; older but still widely used.
Nurtec faces competition from these biologics, which are often prescribed for preventive therapy, whereas Nurtec targets both acute and preventive needs.
Price Point and Reimbursement Landscape
Pricing Overview
- Wholesale Acquisition Cost (WAC): ~$1,950 per 30-count (75 mg) box of Nurtec ODT (April 2023).[4]
- Average Selling Price (ASP): Slightly lower than WAC, depending on pharmacy discounts.
- Patient out-of-pocket: Varies widely based on insurance coverage; copays range from $0 to more than $75 per month.
Reimbursement Policies
Medicare Part D coverage is available, with formulary placements influencing access. Commercial insurance and Medicaid also cover Nurtec, but prior authorization is often required.
Pricing Trends
Increased utilization of Nurtec correlates with price stability, given the drug's patent exclusivity and high efficacy. Patent protections are expected through 2030, with potential for biosimilar or generic threats if patent challenges succeed or exclusivity periods are shortened.
Market Projections to 2030
Revenue Forecasts
| Year |
Estimated global sales |
Major factors influencing growth |
| 2023 |
$520 million |
Continued adoption, increased physician awareness |
| 2025 |
$700 million |
Expansion into global markets, broader indications |
| 2030 |
$1.2 billion |
Competitive pressure, potential biosimilar entry |
Price Projections
- 2023–2025: Stable WAC price barring policy changes. Incremental increases aligned with healthcare inflation.
- 2026–2030: Possible price reductions if biosimilars or generics enter the market or as reimbursement pressures increase.
Risks
- Loss of patent exclusivity could lead to generic entry, reducing prices by 50% or more.
- Regulatory or legislative changes affecting drug pricing and reimbursement.
- Competitive breakthroughs in migraine treatment, such as oral CGRP monoclonal antibodies.
Key Takeaways
- Nurtec ODT (NDC 42291-0927) is a leading oral CGRP antagonist with revenues expected to grow, driven by increasing migraine prevalence and expansion into global markets.
- Current pricing around $1,950 per month signifies high-value therapy, with reimbursement policies supporting broad access.
- Revenue growth beyond 2025 hinges on patent protection, market expansion, and competitive landscape developments.
- The market faces significant risk of price erosion if biosmirals or competing therapies gain widespread adoption.
- Long-term projections suggest potential revenues could reach $1.2 billion by 2030 if market conditions remain favorable.
FAQs
Q1. How does Nurtec compare pricing-wise with other migraine therapies?
Nurtec’s WAC of roughly $1,950 per 30-dose box is higher than older triptans but competitive with injectable CGRP therapies, which are often administered monthly and can cost over $6,000 annually.
Q2. What is the patent life remaining for Nurtec?
The original patent protections extend until 2030. Patent challenges or extensions could alter this timeline.
Q3. Are biosimilars expected for Rimegepant?
Biosimilars are unlikely due to its small-molecule status; instead, generics may enter once patents expire, potentially cutting prices by over 50%.
Q4. How does insurance reimbursement affect Nurtec sales?
Coverage is generally comprehensive with newer policies, but prior authorizations and copay requirements can limit access and impact patient adherence.
Q5. What are the key competitive threats?
Generic entry post-2030, new oral or injectable CGRP therapies, and combination treatments could impact Nurtec's market exclusivity and pricing.
References
[1] MarketsandMarkets. (2022). Migraine Therapeutics Market.
[2] IQVIA. (2022). IMS Health Data.
[3] World Health Organization. (2019). Migraine Fact Sheet.
[4] RedBook. (2023). Average Wholesale Price Data.
